|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
|
|
| 18F-fluciclovine PET/CT in Patients with Suspected Recurrent Prostate Cancer |
| Bital Savir-Baruch, MD |
| Phillip Koo welcomes Bital Savir-Baruch who is presenting a review of prostate cancer imaging with 18F-FACBC fluciclovine (Axumin®) in men with suspected prostate cancer recurrence. |
|
|
|
|
|
|
|
|
|
|
|
|
CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer
|
|
Michael J. Morris, MD
|
| Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
The Use of Novel Imaging Methods in Prostate Cancer
|
Stefano Fanti, MD
Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care.
|
|
|
|
|
|
|
|
|
|
|
| Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer
|
|
|
| Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced that the first patients have been dosed at clinical trial sites in its Phase 3 SPOTLIGHT clinical trial of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent. Patient enrollment now underway in Phase 3 SPOTLIGHT as well as LIGHTHOUSE clinical trials in prostate cancer.
|
|
|
|
|
|
| The Role of (fast) Bi-Parametric MRI versus Multi-Parametric MRI and TRUS-biopsy for Detecting Clinically Significant Prostate Cancer in Biopsy Naïve Men with Elevated PSA
|
| Jelle Barentsz, MD, Ph.D.
|
| Professor Barentsz presented his group’s work assessing fast bi-parametric MRI for the detection of prostate cancer. As Dr. Barentsz notes, we have three level 1a prospective clinical trials concluding that we should be doing an MRI before a biopsy.
|
|
|
|
|
|
|
|
|
|
|
| Imaging as Triage for Prostate Cancer |
| Hashim U. Ahmed, MD, Ph.D., BM, Bch |
| As part of a plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting assessing “Modern prostate cancer imaging in daily practice”, Dr. Ahmed examined the role of imaging as a triage approach in patients suspected of having prostate cancer. |
|
|
|
|
|
| Ultrasound in Prostate Cancer Imaging: Dead or Ready to Get Started?
|
| Christophe Mannaerts, MD
|
| Christophe Mannaerts examined the role of ultrasound in prostate cancer imaging. While transrectal ultrasound is widely used to guide prostate biopsy, traditional grayscale ultrasound is unreliable in prostate cancer diagnosis. However, there have been many newer approaches to ultrasound that have been introduced to improve both the sensitivity and specificity.
|
|
|
|
|
|
|
|
|
|
|
| A Peek into the Future: Artificial Intelligence and Prostate Cancer Imaging |
| Olivier Rouviere, MD, PhD |
| At the European Association of Urology Virtual 2020 meeting, Olivier Rouviere, MD, PhD, concluded the plenary session on “Modern prostate cancer imaging in daily practice,” by discussing the impact of artificial intelligence and prostate cancer imaging. Dr. Rouviere notes that machine learning entails training a machine to discriminate prostate cancer on magnetic resonance images using pattern recognition and statistical tools. |
|
|
|
|
|
|
